Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Display # 
Title Published Date
Bayer Science & Education Foundation launches new round of funding 08 June 2016
Grants4Apps Accelerator 2016: You imagine, Bayer supports 10 May 2016
Bayer off to a successful start in 2016 26 April 2016
2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 25 April 2016
Bayer continues to grow its open innovation activities 09 February 2016
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries 08 January 2016
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases 21 December 2015
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization 20 November 2015
Bayer aligns organization with Life Science businesses 18 September 2015
New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents 16 September 2015
Bayer significantly improves earnings 29 July 2015
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million 10 June 2015
Xarelto® approved in China across three indications in the area of venous and arterial thromboembolism 07 May 2015
Strong start to the year for Bayer 30 April 2015
Bayer aspires to significantly expand Life Science businesses 11 March 2015
Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study 10 February 2015
Bayer operationally strong - strategic focus on Life Science businesses 02 November 2014
Bayer supports World Thrombosis Day as founding global partner 13 October 2014
Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion 01 October 2014
Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies 08 September 2014

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

FDA approves first buprenorphine im…

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designe...

Read more

Fasting-like diet reduces multiple …

Evidence is mounting that a diet mimicking the effects of fasting has health benefits beyond weight loss, with a new USC-led study indicating that it may reduce symptoms ...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Exercise, future anticancer therapy…

Several studies have demonstrated the benefits of exercise to improve the quality of life of people with cancer. But Dr. Fred Saad, urologist-oncologist and researcher at...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]